Informatie:
Fout:
ID
34383
Beschrijving
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00806481
Link
https://clinicaltrials.gov/show/NCT00806481
Trefwoorden
Versies (1)
- 17-01-19 17-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Kidney Failure, Chronic NCT00806481
Eligibility Kidney Failure, Chronic NCT00806481
- StudyEvent: Eligibility
Similar models
Eligibility Kidney Failure, Chronic NCT00806481
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
chronic kidney disease patients aged 18 to 80 years
boolean
ID.2
Item
chronic kidney disease stage 3 (defined as a glomerular filtration rate of 30-60 ml/min/1.73m2)
boolean
ID.3
Item
office blood pressure controlled to less than 140/90 mmhg for 12 months before entry into the study
boolean
ID.4
Item
total cholesterol less than 5.5 mmol/l
boolean
ID.5
Item
existing or previous treatment within 1 year with a phosphate binder or vitamin d analogue
boolean
ID.6
Item
uncontrolled hyperphosphataemia (serum phosphate >1.8 mmol/l)
boolean
ID.7
Item
uncontrolled secondary hyperparathyroidism (pth >80 pg/ml)
boolean
ID.8
Item
diabetes mellitus
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
moderate-severe cardiac valvular disease
boolean